KMT2Ar leukemias, as well as MYC-driven B cell lymphomas, are highly sensitive to inhibition of BCL2 through venetoclax treatment (Vandenberg and Cory 2013; Niu et al. 2014; Khaw et al. 2016). This evidence concerns the gene BCL2 and B-cell non-Hodgkin lymphoma.